JCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier Series
HYOGO, Japan, June 18, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced the launch of a film featured in The Next Frontier, a global branded film series presented by the Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions. The Next Frontier series explores how biotechnology can be used effectively to address urgent challenges the world faces.
As part of the series, the JCR-sponsored film tells the story of a family affected by mucopolysaccharidosis type II (MPS II, or Hunter syndrome), a rare, progressive, life-threatening lysosomal storage disorder.
"This film demonstrates the hardships and challenges that people living with MPS II face on a daily basis from the perspective of a family affected by this devastating and life-limiting disease," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "We are honored to participate in this important video series to shine a spotlight on MPS II and increase awareness worldwide about this debilitating rare disease for which patients desperately need new treatment options. This impactful story is a great illustration of how collaborating with patient communities drives progress. We are committed to supporting the MPS II patient community, and we look forward to advancing our investigational therapy for people living with MPS II."
The Next Frontier series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection. The series debuted at the BIO International Convention, taking place from June 16-19, 2025.
Watch the JCR film here, and view the full The Next Frontier series here.
About The Next Frontier SeriesThe Next Frontier is a global branded film series presented by Biotechnology Innovation Organization (BIO) and produced by BBC StoryWorks Commercial Productions, and it explores how biotechnology can be used effectively to address urgent challenges the world faces. The series highlights biotechnology's potential to help create a healthier and more sustainable future for all. The series delves into how powerful storytelling can turn complexity into clarity and breakthrough science into emotional connection and features the tools that help the public not just understand biotech but believe in its potential. If the future depends on science, it also depends on the stories we tell.
About Biotechnology Innovation Organization (BIO)BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services, worldwide. BIO members are at the forefront of researching and developing innovative biotechnologies across healthcare, agriculture, industry, and the environment. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. BIO is helping to drive a revolution that aims to cure patients, protect our climate, and nourish humanity.
About Mucopolysaccharidosis Type II (Hunter Syndrome)Mucopolysaccharidosis type II (MPS II, or Hunter syndrome) is an X-linked recessive lysosomal storage disorder caused by a deficiency of iduronate-2-sulfatase, an enzyme that breaks down complex carbohydrates called glycosaminoglycans (GAGs, also known as mucopolysaccharides) in the body. Hunter syndrome, which affects an estimated 2,000-3,000 individuals worldwide (according to JCR research), gives rise to a wide range of somatic and neurological symptoms. The current standard of care for Hunter syndrome is enzyme replacement therapy. Central nervous system symptoms related to MPS II have been unmet medical needs so far.
About JCR Pharmaceuticals Co., Ltd.JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: https://jcrpharm.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618017975/en/
Contacts
Investors & Media:JCR Pharmaceuticals Co., Ltd.Corporate Communicationsir-info@jp.jcrpharm.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The research findings, detailing the role of N-glycosylation in lysosomal targeting, have been published in the International Journal of Biological Macromolecules, a prestigious SCIE-indexed journal. Hunter syndrome (MPS II) is a rare genetic disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene, resulting in a deficiency of the IDS enzyme, which is essential for the degradation of glycosaminoglycans (GAGs). This deficiency leads to the progressive accumulation of GAG within lysosomes, causing a range of symptoms. Thus, effective treatment relies on delivering the therapeutic enzyme to lysosomes to facilitate GAG breakdown. For effective lysosomal targeting, the N-glycan structures of the therapeutic enzyme must contain mannose-6-phosphate (M6P). M6P acts as a targeting signal, guiding the enzyme to bind to cells, facilitating its uptake and delivery into lysosomes to degrade GAGs. The research utilized high-resolution Orbitrap mass spectrometry to analyze the site-specific N-glycan structures of idursulfase beta (Hunterase). A total of 42 N-glycan structures were identified, with two sites, Asn221 and Asn255, found to be predominantly modified with bis-mannose-6-phosphate (bis-M6P), a structure containing two phosphate groups. The research team explains that this bis-M6P structure ensures the efficient and stable delivery of idursulfase beta (Hunterase) to lysosomes. The research team also demonstrated idursulfase beta's high-affinity binding to the M6P receptors using surface plasmon resonance. Additionally, fluorescence-labeled cellular studies confirmed efficient uptake and lysosomal delivery of idursulfase beta (Hunterase). Moreover, several N-glycan structures of idursulfase beta (Hunterase) were found to be modified with sialic acid, which is known to prolong the enzyme's circulation in the blood, extending its half-life. Hunterase (idursulfase beta), according to GC Biopharma, is highly effective for treating Hunter syndrome due to its targeted lysosomal delivery, driven by N-glycan structures modified with M6P and prolonged circulation enabled by sialic acid modifications. "This study analyzed the lysosomal delivery mechanism of Hunterase (idursulfase beta), supported by robust scientific evidence," said Jae Uk Jeong, Head of R&D at GC Biopharma. "With clear evidence of its therapeutic effectiveness, patients with Hunter syndrome can have greater confidence in using Hunterase throughout their treatment journey." About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo®(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kimshkim20@ Yelin Junyelin@ Yoonjae Nayjy6520@ View original content to download multimedia: SOURCE GC Biopharma Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Surf Bio Announces Peer-Reviewed Publication Demonstrating Feasibility of Subcutaneous Delivery of Ultra-Concentrated Biologics
Research conducted by Stanford University and published in Science Translational Medicine shows successful injection of protein formulations exceeding 500 mg/mL PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Surf Bio, a biopharmaceutical company transforming the delivery of antibodies and biologics, announced today that a peer-reviewed study conducted by researchers at Stanford University and published in Science Translational Medicine has demonstrated the feasibility of reformulating biologics for subcutaneous delivery at ultra-high concentrations. The study's lead author, Carolyn Jons, Ph.D., and collaborators reported that spray-dried microparticle formulations surpassed 500 mg/mL and were delivered through a standard 27-gauge needle at clinically relevant forces, marking a potential breakthrough in expanding access to infusion-only therapies. The paper, entitled, "Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics," may be accessed via the following URL: "The research addresses one of the most persistent challenges in drug delivery: how to administer high-dose biologic therapies without the need for intravenous infusion," stated Dr. Jons. "Many existing protein-based therapies require hospital or clinic-based infusions due to their large volume, instability, or reconstitution requirements. This study describes a spray-drying process that converts protein formulations into microparticles suspended in a non-solvent liquid carrier, resulting in a stable, ready-to-inject solution that meets the viscosity and force thresholds for subcutaneous administration." "This research provides a critical foundation for our work at Surf Bio and highlights the significant potential of our SnapShot™ technology," said Bryan Mazlish, CEO of Surf Bio. "We're leveraging this licensed platform to help unlock subcutaneous administration for therapies that have historically required IV infusion. Our goal is to translate this innovation into ready-to-inject, patient-friendly formulations that reduce burden on the healthcare system while enabling self-administration at home." Importantly, the platform utilizes a polymer excipient that improves stability during spray drying and enhances the injectability of the final formulation. In preclinical models, these microparticles were shown to maintain protein activity and structure, achieving doses well beyond those currently accessible with drug products approved for subcutaneous delivery. The technology does not require any specialized delivery device and can be used with commercially available autoinjectors and standard fill-finish processes. About Surf Bio:Surf Bio is a biopharmaceutical company transforming the delivery of antibodies and biologics via its SnapShot™ technology platform. Powered by the Company's proprietary polymer, SnapShot enables the development of ultra-high concentration formulations of monoclonal antibodies (mAbs) and biologics that can be administered using a single, standard autoinjector shot. To date, in-vitro and in-vivo safety and efficacy data have demonstrated that SnapShot enables drug developers to produce very high concentration, subcutaneous formulations of novel mAbs and biologics. Surf Bio was launched by the founders of Bigfoot Biomedical and AGC to commercialize a breakthrough drug delivery technology developed in the Appel lab at Stanford University. For more information about Surf Bio, visit Contact for Surf Bio:Tiberend Strategic Advisors, Reissereiss@ View original content to download multimedia: SOURCE Surf Bio, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
2 days ago
- Newsweek
Breakthrough Nanobody Tech Hits Lung Cancer Cells Like a Drone Strike
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A nanobody-based technology can precisely identify and attack lung cancer cells—sparing surrounding healthy tissue. This is the promise of researchers at the Bio-Nano Research Center at the Korea Research Institute of Bioscience and Biotechnology (KRIBB), who say that the approach could improve cancer therapy by reducing harmful side effects and maximizing efficiency. The study showed treatment potential for lung adenocarcinoma—a type of non-small cell lung cancer—in particular. This is the most common type of lung cancer seen in the U.S., accounting for 45 percent of all cases in 2021, according to the Centers for Disease Control and Prevention (CDC). Lung adenocarcinoma often has late detection and high recurrence rates after treatment. Mature man in pain coughing on sofa at home. Mature man in pain coughing on sofa at home. brizmaker/Getty Images Current chemotherapies can attack healthy cells, fail to deliver drugs precisely to cancer cells and lead to side effects. With this in mind, the team developed the 'A5 nanobody'—a tiny antibody that binds to a protein called CD155 found in high abundance on lung cancer cells. The A5 nanobody is around 10 times smaller than conventional antibodies, helping it to penetrate deep into tissues. Crucially, it can bind selectively to cancer cells, leading to a reduction of more than 50 percent in components of cancer spread. The researchers also engineered a drug delivery system called A5-LNP-DOX, which combines the A5 nanobody with liposomal capsules containing the anticancer drug doxorubicin (DOX). This design acts like a "drone strike," delivering the drug precisely to CD155 targets on the surface of cancer cells, according to the researchers. Pink visual of lung cancer adenocarcinoma cells. Pink visual of lung cancer adenocarcinoma cells. rightdx/Getty Images In the study, A5-LNP-DOX delivered up to three times more drug into cancer cells than conventional methods, significantly enhancing cancer cell death while leaving healthy cells largely unharmed, the researchers found. Tests in animal models and patient-derived organoids showed tumor size reductions of 70–90 percent and substantial increases in cancer cell death markers. Meanwhile, no damage was detected in major organs including the liver, heart or kidneys. "Our study presents a new therapeutic strategy capable of precisely targeting cancer cells and delivering drugs effectively," said study author Juyeon Jung in a statement. "We expect this nanobody-based approach to serve as a versatile platform for treating not only lung cancer but also a variety of other cancers, contributing greatly to the advancement of precision medicine." Newsweek has reached out to the researchers for comment. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about lung cancer? Let us know via health@ Reference Noh, K., Yi, S., Kim, H., Lee, J., Kim, S., Yoo, W., Jung, E., Choi, J., Park, H., Hwang, S., Kang, J. Y., Park, K.-H., Park, H., Lee, Y., Lim, E.-K., Kang, T., & Jung, J. (2025). Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery. Signal Transduction and Targeted Therapy, 10(1), 218.
